ATTR-Mixed clinical trials at UCSF

1 research study open to eligible people

ATTR-mixed is a form of transthyretin amyloidosis that harms the heart and nerves. UCSF is part of a global study that follows patients over many years. UCSF is collecting medical, imaging, and lab data about how the disease changes.

Showing trials for

  • Patients With Transthyretin (ATTR) Amyloidosis

    open to eligible people ages 18-130

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    San Francisco, California and other locations

Last updated: